Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Seminars in Oncology

• Publication date

  1995-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 7481870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients

  2004cited by this paper
• Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

  2004cited by this paper
• Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

  1995cited by this paper
• Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

  1995cited by this paper
• Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).

  1994cited by this paper
• Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.

  1994cited by this paper
• Dose optimisation of carboplatin in adults.

  1994cited by this paper
• Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.

  1994cited by this paper
• Paclitaxel (Taxol) therapy in ovarian carcinoma.

  1993cited by this paper
• Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

  1993cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

  1992cited by this paper
• Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

  1992cited by this paper
• Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.

  1989cited by this paper
• A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Carboplatin in combination therapy for ovarian cancer.

  1988cited by this paper
• Comparison of 51cr Edta Clearance with Formulae in the Measurement of Glomerular Filtration Rate

  1986cited by this paper
• JMS, successor to cisplatin in advanced ovarian carcinoma?

  1983cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA.

  1969cited by this paper

• Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

  2021cites this paper
• Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.

  2020cites this paper
• Evaluation du suivi thérapeutique pharmacologique du carboplatine et étude pharmacocinétique/pharmacogénétique de l'étoposide dans le cadre d'un essai clinique de phase II d'intensification thérapeutique en cancérologie

  2018cites this paper
• Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review

  2017cites this paper
• Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?

  2016cites this paper
• Taxanes: their impact on gynecologic malignancy

  2014cites this paper
• An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers

  2012cites this paper
• The Taxoids

  2012cites this paper
• Cancer Chemotherapy Update Paclitaxel, Carboplatin, and Trastuzumab

  2011cites this paper
• Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.

  2011cites this paper
• Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin

  2011cites this paper
• Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin

  2010cites this paper
• Novel Algorithm for More Accurate Calculation of Renal Function in Adults with Cancer

  2008cites this paper
• Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

  2007cites this paper
• Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder

  2006influential citation
• Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer

  2006cites this paper
• Carboplatin dosing accounting for the renal and hematologic status of patients.

  2003cites this paper
• Carboplatin dosing accounting for the renal and hematologic status of patients.

  2003cites this paper
• A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens

  2003cites this paper
• Carboplatin equals cisplatin: but how do I prescribe it?

  2003cites this paper
• Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer

  2002cites this paper
• Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.

  2002cites this paper
• Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.

  2002cites this paper
• Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study.

  2002cites this paper
• Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.

  2002cites this paper
• Clinical Pharmacokinetics of Anticancer Drugs:focus on E7070, methotrexate and paclitaxel

  2002cites this paper
• Aus der Klinik für Hämatologie, Onkologie und Klinische Immunologie der Heinrich-Heine-Universität Düsseldorf

  2002cites this paper
• Non‐Sedating Antihistamines for Premedication in Ambulatory Oncology Patients

  2002cites this paper
• Dosificación de carboplatino: sesgo por sexos y estimaciones inexactas del porcentaje de filtración glomerular

  2002cites this paper
• Clinical Q&A

  2002cites this paper
• Drug interactions with the taxanes: clinical implications.

  2001cites this paper
• Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing

  2001cites this paper
• The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin

  2001cites this paper
• Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer

  2001cites this paper
• Taxol in the Management of Cancers of the Breast and the Ovary

  2000cites this paper
• A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies

  2000cites this paper
• Pharmacokinetically Guided Administration of Chemotherapeutic Agents

  2000cites this paper
• A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

  2000cites this paper
• [Pharmacokinetics and individual dose adjustment of carboplatin].

  2000cites this paper
• Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure

  2000cites this paper
• Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.

  1999cites this paper
• Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.

  1999cites this paper
• Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.

  1999cites this paper
• Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer

  1999cites this paper
• Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma A multicenter GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study

  1998cites this paper
• Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

  1998cites this paper
• Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study.

  1998cites this paper
• New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.

  1998cites this paper
• Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae

  1998cites this paper
• A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte‐colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

  1998cites this paper
• Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens

  1998cites this paper
• Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy

  1998cites this paper
• Paclitaxelof its Use in the Treatment of Metastatic Breast Cancer and Ovarian and Other Gynaecological Cancers

  1998cites this paper
• Biology of thrombopoiesis and the role of Mpl ligand in the production and function of platelets.

  1997cites this paper
• Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

  1997cites this paper
• Taxanes in ovarian cancer treatment.

  1997cites this paper
• Clinical Pharmacokinetics and Dose Optimisation of Carboplatin

  1997cites this paper
• Review : Pharmacokinetics and pharmacodynamics of the taxanes

  1997cites this paper
• Review : Cremophor: Pharmacological activity of an "inert" solubiliser

  1997cites this paper
• How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.

  1997cites this paper
• Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.

  1997cites this paper
• Place du paclitaxel (Taxol®) lors de la chimiothérapie de première ligne des adénocarcinomes ovariens

  1997cites this paper
• Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial

  1996cites this paper
• Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

  1996cites this paper
• Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.

  1996cites this paper
• Current Drug Treatment Guidelines for Epithelial Ovarian Cancer

  1996cites this paper
• Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel.

  1996cites this paper
• Correspondence

  1888cites this paper